David Weinstein
Tracked across 2 events · 12 articles · First seen Aug 20, 2026 · Last active Sep 23, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Regulatory
Impact: GSDIa expert who commented on the demanding nature of current treatment and the significance of the approval.
Aug 20, 2026 · 6 articles
Business
Lunai Bioworks announced an exclusive worldwide license and collaboration agreement with Tanaist to add human cellular phenotyping to its Parkinson's disease discovery and validation platform. Under the deal, Lunai gains exclusive rights to Tanaist's licensed…
Impact: David Weinstein, CEO of Lunai Bioworks, commented on the collaboration and the next steps for validating the three Parkinson's subtypes. His statements frame the strategic rationale for the Tanaist agreement.
Sep 22, 2026 · 6 articles
ERGEN INTELLIGENCE
Track David Weinstein live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard